Last reviewed · How we verify
Vehicle Foam
Vehicle Foam is a Small molecule drug developed by Vyne Therapeutics Inc.. It is currently FDA-approved for Topical dermatological conditions (specific indication dependent on active ingredient formulated in vehicle). Also known as: Placebo, Vehicle, Quinnova Foam Vehicle, placebo.
Vehicle Foam is a topical foam formulation designed to deliver active pharmaceutical ingredients to the skin surface for localized therapeutic effect.
Vehicle Foam is a topical treatment used to study various skin conditions, including psoriasis, acne, and dermatitis, in clinical trials. It has been compared to other treatments such as Dermoval/Dermovate and Diprosone in a vasoconstriction trial.
At a glance
| Generic name | Vehicle Foam |
|---|---|
| Also known as | Placebo, Vehicle, Quinnova Foam Vehicle, placebo |
| Sponsor | Vyne Therapeutics Inc. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Vehicle Foam serves as a delivery system or base formulation for topical medications. As a foam, it provides improved spreadability, cosmetic elegance, and potentially enhanced penetration compared to traditional creams or ointments. The specific active ingredient and mechanism depend on what therapeutic agent is incorporated into the foam vehicle.
Approved indications
- Topical dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)
Common side effects
- Local skin irritation
- Contact dermatitis
- Application site reactions
Key clinical trials
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis (PHASE3)
- A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (PHASE3)
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (PHASE3)
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
- A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle Foam CI brief — competitive landscape report
- Vehicle Foam updates RSS · CI watch RSS
- Vyne Therapeutics Inc. portfolio CI
Frequently asked questions about Vehicle Foam
What is Vehicle Foam?
How does Vehicle Foam work?
What is Vehicle Foam used for?
Who makes Vehicle Foam?
Is Vehicle Foam also known as anything else?
What development phase is Vehicle Foam in?
What are the side effects of Vehicle Foam?
Related
- Manufacturer: Vyne Therapeutics Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Topical dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)
- Also known as: Placebo, Vehicle, Quinnova Foam Vehicle, placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing